Literature DB >> 9779349

Current and future therapy of invasive fungal infections.

V T Andriole1.   

Abstract

Major increases in the incidence of systemic fungal infections have been observed during the past three decades, particularly in immunocompromised patients. A critical need exists for new antifungal agents to treat these life-threatening invasive fungal infections. The review of the development of antifungal therapy provided in this chapter indicates the increased interest in this very special area of infectious diseases. Even though newer and less toxic antifungal agents are currently available for clinical use, innovative research in antifungal drug discovery may eventually produce more promising antifungal agents.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9779349

Source DB:  PubMed          Journal:  Curr Clin Top Infect Dis        ISSN: 0195-3842


  4 in total

1.  Nebulized amphotericin B combined with intravenous amphotericin B in rats with severe invasive pulmonary aspergillosis.

Authors:  Elisabeth J Ruijgrok; Marcel H A M Fens; Irma A J M Bakker-Woudenberg; Els W M van Etten; Arnold G Vulto
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

2.  Isolation of Candida famata from a patient with acute zonal occult outer retinopathy.

Authors:  Luis Carrasco; Marta Ramos; Rebeca Galisteo; Diana Pisa; Manuel Fresno; María Eugenia González
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

3.  Crystal structures of the fungal pathogen Aspergillus fumigatus protein farnesyltransferase complexed with substrates and inhibitors reveal features for antifungal drug design.

Authors:  Mark F Mabanglo; Michael A Hast; Nathan B Lubock; Homme W Hellinga; Lorena S Beese
Journal:  Protein Sci       Date:  2014-01-31       Impact factor: 6.725

Review 4.  Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment.

Authors:  F P Gullo; S A Rossi; J de C O Sardi; V L I Teodoro; M J S Mendes-Giannini; A M Fusco-Almeida
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-07-04       Impact factor: 3.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.